Valuation : Carmat SA

Market Cap 6.15M 7.13M 5.82M 5.27M 9.9M 681M 9.95M 69.11M 26.58M 347M 26.79M 26.2M 1.1B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 68.76M 56.1M 50.85M 95.39M 6.57B 95.88M 666M 256M 3.34B 258M 253M 10.56B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.0962
0.14
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/03/25 Sell

Chairman

1,343,333 2.3347%
13/03/25 Buy

Chairman

1,343,333 2.3347%
29/05/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-33.56%-98.53% 7.08M
+0.81%-10.26%-30.03%-9.24% 104B
-1.66%-5.22%-29.15%-5.53% 11.67B
-0.75%-4.41%+93.94%+123.30% 10.04B
-1.34%-3.93%-55.03%-71.49% 3.99B
-2.84%-6.02%-30.57%+30.74% 2.4B
+4.58%+12.02%-14.66%-68.39% 1.97B
+1.47%-6.79% - - 1.81B
-2.10%-3.88%-24.51%-29.82% 1.53B
Average -0.17%-3.39%-15.45%-16.12% 15.22B
Weighted average by Cap. +0.38%-10.17%-21.21%-1.30%

Financials

2023 2024
Net sales 3.84M 4.45M 3.63M 3.29M 6.18M 425M 6.21M 43.15M 16.59M 216M 16.72M 16.36M 684M 7.34M 8.52M 6.95M 6.3M 11.82M 814M 11.88M 82.59M 31.76M 414M 32.01M 31.31M 1.31B
Net income -53.87M -62.52M -51.01M -46.23M -86.73M -5.97B -87.17M -606M -233M -3.04B -235M -230M -9.6B -51.4M -59.65M -48.66M -44.11M -82.75M -5.7B -83.17M -578M -222M -2.9B -224M -219M -9.16B
Net Debt 49.64M 57.61M 47M 42.6M 79.92M 5.5B 80.32M 558M 215M 2.8B 216M 212M 8.85B 53.1M 61.63M 50.28M 45.57M 85.5M 5.89B 85.93M 597M 230M 3B 231M 226M 9.47B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!